Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study

American Heart Journal

Volumn 157, Issue 3, 2009, Pages 457-466

  Cleland, John G F ^a   Calvert, Melanie J ^b   Verboven, Yves ^c   Freemantle, Nick ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MEDTRONIC BAKKEN RESEARCH CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SURVIVAL;

AGED; CARDIAC PACING, ARTIFICIAL; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 60649088431     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.11.006     Document Type: Article

References (44)

1. Cleland J.G.F. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 4 (2002) 243-247
2. Rector T.S., Tschumperlin L.K., Kubo S.H., et al. Use of the living with heart failure questionnaire to ascertain patients' perceptives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1 (1995) 201-206
3. Lewis E.F., Johnson P.A., Johnson W., et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Trans 20 (2001) 1016-1024
4. Hobbs F.D.R., Kenkre J.E., Roalfe A.K., et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 23 (2002) 1867-1876
5. Juenger J., Schellberg D., Kraemer S., et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87 (2002) 235-241
6. Stewart A.L., Greenfled S., Hays R.D., et al. Functional status and wellbeing of patients with chronic conditions. Results from the medical outcomes study. JAMA 262 (1989) 907-913
7. Ekman I., Fagerberg B., and Lundman B. Health-related quality of life and sense of coherence among elderly patients with severe chronic heart failure in comparison with healthy controls. Heart & Lung: J Acute Crit Care 31 (2002) 94-101
8. Calvert M.J., Freemantle N., and Cleland J.G.F. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF Study. Eur J Heart Fail 7 (2005) 243-251
9. Abraham W.T., Fisher W.G., Smith A.L., et al., for the MIRACLE Study Group. Cardiac resynchronisation in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
10. Bristow M.R., Saxon L.A., Boehmer J., et al., for the comparison of medical therapy padihfCi. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
11. Cazeau S., Leclerc C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 (2001) 873-880
12. Cleland J.G.F., Daubert J.-C., Erdmann E., et al., for the Cardiac Resynchronisation-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
13. Gras D., Lunati M., Wellens H.J.J., et al. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace 9 (2007) 516-522
14. Cleland J.G.F., Daubert J.C., Erdmann E., et al. Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony. Eur J Heart Fail 3 (2001) 481-489
15. Cleland J.G., Daubert J.C., and Erdmann E. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 7 (2005) 205-214
16. Rector T.S., and Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and validity during a randomized, double-blind placebo-controlled trial of pimobendan. Am Heart J 124 (1992) 1017-1025
17. EQ-5D. Measure of health-related quality of life developed by the Euroqol Group. Available at: http://www.euroqol.org. Last accessed January 4, 2009.
18. Dolan P. Modeling valuations for Euroqol health states. Med Care 35 (1997) 1095-1108
19. Kind P., Hardman G., and Macran S. UK population norms for EQ-5D (1999), University of York Press, York, United Kingdom [Discussion Paper 172.
20. Badia X., Roset M., and Herdman M. A comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States. Med Decis Making 21 (2001) 7-16
21. Nyman J.A., Barleen N.A., and Dowd B.E. Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care 45 (2007) 618-628
22. Sullivan P.W., Lawrence W.F., and Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43 (2005) 736-749
23. Greiner W., Claes C., Busschbach J.J.V., et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 6 (2005) 124-130
24. Value sets produced as part of the EuroQol Group enterprise. Available at: http://www.euroqol.org. Last accessed January 4, 2009.
25. Johnson J., Luo N., Shaw J., et al. Valuations of EQ-5D health states: are the United States and United Kingdom different. Med Care 43 (2005) 221-228
26. Lewis J.A. ICH harmonised tripartite guideline. statistical principles for clinical trials (ICH E9). Stat Med 18 (1999) 1905-1942
27. Harrell F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
28. Walters S.J., and Brazier J.E. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14 (2005) 1523-1532
29. Rogers W.J., Johnstone D.E., and Yusuf S. Quality of life among 5025 patients with left ventricular dysfunction randomised between placebo and enalapril. The Studies Of Left-Ventricular Dysfunction. J Am Coll Cardiol 23 (1994) 393-400
30. Lader E., Egan D., Hunsberger S., et al. The effect of digoxin on the quality of life in patients with heart failure. J Cardiac Failure 9 (2008) 4-12
31. Fowler M.B. Effects of beta blockers on symptoms and functional capacity in heart failure. Am J Cardiol 80 (1997) 55L-58L
32. Majani G., Giardini A., Opasich C., et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the valsartan heart failure trial. J Card Fail 11 (2005) 253-259
33. Cleland J.G.F., Daubert J.C., Erdmann E., et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure. The CARE-HF trial extension phase. Eur Heart J 27 (2006) 1928-1932
34. Machin D., Campbell M., Fayers P., et al. Sample size tables for clinical studies. 2nd ed. (1997), Blackwell Science, Oxford, England
35. Friedman M.M. Gender differences in the health related quality of life of older adults with heart failure. Heart Lung: J Acute Crit Care 32 (2003) 320-327
36. Stromberg A., and Martensson J. Gender differences in patients with heart failure. J Cardiovasc Nurs 2 (2003) 7-18
37. Haworth J.E., Moniz-Cook E., Clark A.L., et al. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. Eur J Heart Fail 7 (2005) 803-808
38. Godfrey C.M., Harrison M.B., Friedberg E., et al. The symptom of pain in individuals recently hospitalized for heart failure. J Cardiovasc Nurs 22 (2007) 368-374
39. Hoppe U.C., Casares J.M., Eiskjaer H., et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114 (2006) 18-25
40. Cleland J.G.F., Charlesworth A., Lubsen J., et al. A comparison of the effects of carvedilol and metroprolol on "well-being," morbidity and mortality (the patient journey) in patients with heart failure: a report from the Carvedilol or Metoprolol European Trial (COMET). J Am Coll Cardiol 47 (2006) 1603-1611
41. Yao G., Freemantle N., Calvert M., et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28 (2007) 42-51
42. Cleland J.G.F., Nasir M., and Tageldien A. Cardiac resynchronization therapy or atriobiventricular pacing-what should it be called. Natl Clin Pract Cardiovasc Med 4 (2007) 90-101
43. Cleland J.G.F., Coletta A.P., and Clark A.L. Clinical trials update from the Heart Failure Society of America Meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 8 (2006) 764-766
44. Cleland J.G.F., Louis A.A., Rigby A.S., et al., on behalf of the TEN-HMS investigators. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death. J Am Coll Cardiol 45 (2005) 1654-1664